Related Experiment Video
Updated: Apr 18, 2026

Ultrasound-guided Transthoracic Intramyocardial Injection in Mice
Published on: August 5, 2014
Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience
Jenna M Murray1, Amy Hellinger, Roger Dionne
1Department of Cardiology, Boston Children's Hospital, Boston, USA.
Insights
A dedicated pediatric cardiac anticoagulation program effectively manages warfarin therapy in children with congenital heart disease. This specialized service improves time in therapeutic range and patient satisfaction, addressing unique challenges in pediatric anticoagulation.
Area of Science:
- Pediatric Cardiology
- Pharmacology
- Clinical Management
Background:
- Congenital heart disease (CHD) is a leading cause of stroke in children, often requiring anticoagulation.
- Warfarin therapy in pediatric patients presents unique challenges due to narrow therapeutic index, drug/diet interactions, small size, and specific cardiac conditions.
- Lack of established guidelines complicates safe and effective anticoagulation management in this vulnerable population.
Purpose of the Study:
- To describe the development and outcomes of a dedicated pediatric cardiac anticoagulation service.
- To centralize management of outpatient anticoagulation for pediatric cardiac patients.
- To establish a disease-specific resource and adapt to evolving anticoagulation trends.
Main Methods:
- Establishment of a multidisciplinary Cardiac Anticoagulation Monitoring Program (CAMP) at Boston Children's Hospital in 2009.
- Centralized management by a dedicated team including pediatric cardiology, nurse practitioners, pharmacy, and nutrition.
- Enrollment of over 240 patients (5 months to 55 years) with various cardiac indications over 5 years.
Main Results:
- The CAMP service achieved a favorable overall international normalized ratio (INR) time in therapeutic range (TTR) of 67% (81% with a 0.2 margin), showing steady improvement.
- Common indications included prosthetic valves (34%), Fontan prophylaxis (20%), and atrial arrhythmias (11%).
- Development of pediatric-specific guidelines for pharmacogenomics, procedural bridging, and novel anticoagulants, alongside high patient/provider satisfaction.
Conclusions:
- A dedicated pediatric cardiac anticoagulation program provides a safe and effective strategy for standardizing care.
- Such programs are associated with high patient and provider satisfaction.
- These specialized services can adapt to emerging trends in anticoagulation therapy for pediatric cardiology patients.
Abstract:
Congenital heart disease is the leading cause of stroke in children. Warfarin therapy can be difficult to manage safely in this population because of its narrow therapeutic index, multiple drug and dietary interactions, small patient size, high-risk cardiac indications, and lack of data to support anticoagulation recommendations. We sought to describe our institution's effort to develop a dedicated cardiac anticoagulation service to address the special needs of this population and to review the literature. In 2009, in response to Joint Commission National Patient Safety Goals for Anticoagulation, Boston Children's Hospital created a dedicated pediatric Cardiac Anticoagulation Monitoring Program (CAMP). The primary purpose was to provide centralized management of outpatient anticoagulation to cardiac patients, to serve as a disease-specific resource to families and providers, and to devise strategies to evolve clinical care with rapidly emerging trends in anticoagulation care. Over 5 years the CAMP Service, staffed by a primary pediatric cardiology attending, a full-time nurse practitioner, and administrative assistant with dedicated support from pharmacy and nutrition, has enrolled over 240 patients ranging in age from 5 months to 55 years. The most common indications include a prosthetic valve (34 %), Fontan prophylaxis (20 %), atrial arrhythmias (11 %), cardiomyopathy (10 %), Kawasaki disease (7 %), and a ventricular assist device (2 %). A patient-centered multi-disciplinary cardiac anticoagulation clinic was created in 2012. Overall program international normalized ratio (INR) time in therapeutic range (TTR) is favorable at 67 % (81 % with a 0.2 margin) and has improved steadily over 5 years. Pediatric-specific guidelines for VKOR1 and CYP2C9 pharmacogenomics testing, procedural bridging with enoxaparin, novel anticoagulant use, and quality metrics have been developed. Program satisfaction is rated highly among families and providers. A dedicated pediatric cardiac anticoagulation program offers a safe and effective strategy to standardize anticoagulation care for pediatric cardiology patients, is associated with high patient and provider satisfaction, and is capable of evolving care strategies with emerging trends in anticoagulation.
More Related Videos
09:08Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies
Published on: May 24, 2021
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019